Philip E Castle1, Barbara Fetterman, Nancy Poitras, Thomas Lorey, Ruth Shaber, Walter Kinney. 1. From the Division of Cancer Epidemiology and Genetics, National Cancer Institute, National Institutes of Health, Department of Health and Human Services, Bethesda, Maryland; Regional Laboratory, Kaiser Permanente Northern California, Berkeley, California; Women's Health Research Institute and Division of Gynecologic Oncology, Kaiser Permanente Medical Care Program, Oakland, California.
Abstract
OBJECTIVE: To estimate the 5-year age group-specific test positives for Pap tests and human papillomavirus (HPV) testing in a large, general screening population of women 30 and older. METHODS: Using data from Kaiser Permanente Northern California, a large health maintenance organization that introduced cotesting in 2003, we evaluated the cotesting results overall and by 5-year age groups. Women (n=580,289) who opted for and underwent cotesting (n cotests=812,598) between January 2003 and April 2008 were included in the analysis. Pap tests interpreted as atypical squamous cells of undetermined significance (ASC-US) or more severe were considered to be positive. Women were tested for carcinogenic HPV using an assay approved by the U.S. Food and Drug Administration. Binomial exact 95% confidence intervals (CIs) were calculated. RESULTS: Overall, 6.27% (95% CI 6.21-6.32%) of cotests were carcinogenic HPV positive, and only 3.99% (95% CI 3.94-4.03%) cotests had normal cytology and were carcinogenic HPV positive. By comparison, 5.18% (95% CI 5.13-5.23%) of cotests had ASC-US or more severe cytology, and 2.87% (95% CI 2.84-2.91%) of cotests had ASC-US or more severe cytology and were carcinogenic HPV negative. CONCLUSION: In a general screening population, concerns about excessive HPV test positives among women aged 30 years and older are not borne out.
OBJECTIVE: To estimate the 5-year age group-specific test positives for Pap tests and human papillomavirus (HPV) testing in a large, general screening population of women 30 and older. METHODS: Using data from Kaiser Permanente Northern California, a large health maintenance organization that introduced cotesting in 2003, we evaluated the cotesting results overall and by 5-year age groups. Women (n=580,289) who opted for and underwent cotesting (n cotests=812,598) between January 2003 and April 2008 were included in the analysis. Pap tests interpreted as atypical squamous cells of undetermined significance (ASC-US) or more severe were considered to be positive. Women were tested for carcinogenic HPV using an assay approved by the U.S. Food and Drug Administration. Binomial exact 95% confidence intervals (CIs) were calculated. RESULTS: Overall, 6.27% (95% CI 6.21-6.32%) of cotests were carcinogenic HPV positive, and only 3.99% (95% CI 3.94-4.03%) cotests had normal cytology and were carcinogenic HPV positive. By comparison, 5.18% (95% CI 5.13-5.23%) of cotests had ASC-US or more severe cytology, and 2.87% (95% CI 2.84-2.91%) of cotests had ASC-US or more severe cytology and were carcinogenic HPV negative. CONCLUSION: In a general screening population, concerns about excessive HPV test positives among women aged 30 years and older are not borne out.
Authors: Philip E Castle; Cosette M Wheeler; Diane Solomon; Mark Schiffman; Cheri L Peyton Journal: Am J Clin Pathol Date: 2004-08 Impact factor: 2.493
Authors: N W J Bulkmans; J Berkhof; L Rozendaal; F J van Kemenade; A J P Boeke; S Bulk; F J Voorhorst; R H M Verheijen; K van Groningen; M E Boon; W Ruitinga; M van Ballegooijen; P J F Snijders; C J L M Meijer Journal: Lancet Date: 2007-10-04 Impact factor: 79.321
Authors: Thomas C Wright; Mark Schiffman; Diane Solomon; J Thomas Cox; Francisco Garcia; Sue Goldie; Kenneth Hatch; Kenneth L Noller; Nancy Roach; Carolyn Runowicz; Debbie Saslow Journal: Obstet Gynecol Date: 2004-02 Impact factor: 7.661
Authors: Marie-Hélène Mayrand; Eliane Duarte-Franco; Isabel Rodrigues; Stephen D Walter; James Hanley; Alex Ferenczy; Sam Ratnam; François Coutlée; Eduardo L Franco Journal: N Engl J Med Date: 2007-10-18 Impact factor: 91.245
Authors: Thomas C Wright; L Stewart Massad; Charles J Dunton; Mark Spitzer; Edward J Wilkinson; Diane Solomon Journal: Am J Obstet Gynecol Date: 2007-10 Impact factor: 8.661
Authors: Mark E Sherman; Attila T Lorincz; David R Scott; Sholom Wacholder; Philip E Castle; Andrew G Glass; Iwona Mielzynska-Lohnas; Brenda B Rush; Mark Schiffman Journal: J Natl Cancer Inst Date: 2003-01-01 Impact factor: 13.506
Authors: Walter Kinney; Barbara Fetterman; J Thomas Cox; Thomas Lorey; Tracy Flanagan; Philip E Castle Journal: Gynecol Oncol Date: 2011-01-26 Impact factor: 5.482
Authors: Philip E Castle; Alfio Rausa; Tameka Walls; Patti E Gravitt; Edward E Partridge; Vanessa Olivo; Shelley Niwa; Kerry Grace Morrissey; Laura Tucker; Hormuzd Katki; Isabel Scarinci Journal: Prev Med Date: 2011-04-08 Impact factor: 4.018
Authors: Cosette M Wheeler; William C Hunt; Jack Cuzick; Erika Langsfeld; Amanda Pearse; George D Montoya; Michael Robertson; Catherine A Shearman; Philip E Castle Journal: Int J Cancer Date: 2012-06-20 Impact factor: 7.396
Authors: Vicki B Benard; Mona Saraiya; April Greek; Nikki A Hawkins; Katherine B Roland; Diane Manninen; Donatus U Ekwueme; Jacqueline W Miller; Elizabeth R Unger Journal: J Womens Health (Larchmt) Date: 2013-12-31 Impact factor: 2.681
Authors: Debbie Saslow; Diane Solomon; Herschel W Lawson; Maureen Killackey; Shalini L Kulasingam; Joanna Cain; Francisco A R Garcia; Ann T Moriarty; Alan G Waxman; David C Wilbur; Nicolas Wentzensen; Levi S Downs; Mark Spitzer; Anna-Barbara Moscicki; Eduardo L Franco; Mark H Stoler; Mark Schiffman; Philip E Castle; Evan R Myers Journal: CA Cancer J Clin Date: 2012-03-14 Impact factor: 508.702
Authors: Gaea Moore; Barbara Fetterman; J Thomas Cox; Nancy Poitras; Thomas Lorey; Walter Kinney; Philip E Castle Journal: J Low Genit Tract Dis Date: 2010-04 Impact factor: 1.925
Authors: Mark Schiffman; Laurence M Vaughan; Tina R Raine-Bennett; Philip E Castle; Hormuzd A Katki; Julia C Gage; Barbara Fetterman; Brian Befano; Nicolas Wentzensen Journal: Gynecol Oncol Date: 2015-07-04 Impact factor: 5.482
Authors: Kenneth E Youens; Gregory A Hosler; Paula J Washington; E Patrick Jenevein; Kathleen M Murphy Journal: J Mol Diagn Date: 2011-03 Impact factor: 5.568
Authors: Mona Saraiya; Vicki B Benard; April A Greek; Martin Steinau; Sonya Patel; L Stewart Massad; George F Sawaya; Elizabeth R Unger Journal: Am J Obstet Gynecol Date: 2014-05-06 Impact factor: 8.661
Authors: Rachel L Winer; Jasmin A Tiro; Diana L Miglioretti; Chris Thayer; Tara Beatty; John Lin; Hongyuan Gao; Kilian Kimbel; Diana S M Buist Journal: Contemp Clin Trials Date: 2017-11-04 Impact factor: 2.226